| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 公司成立于1999年，是一家专注于抗血清抗毒素领域的生物医药企业，致力于研究、开发、生产及销售针对生物毒素及生物安全领域的预防和治疗药物。 在蛇伤治疗领域，公司拥有国内蛇伤治疗的唯一特效药抗蛇毒血清系列产品，满足了公共卫生领域的部分应急、突发临床需求。同时，公司抗蛇毒血清为国内独家生产及销售，属于独创独有，截至目前尚无任何国外药企进入国内该市场领域，实现了国内蛇伤应急治疗领域的自主可控。在破伤风治疗领域，公司拥有国内独家生产的马破伤风免疫球蛋白(F(ab')2)用于破伤风的预防和治疗；在狂犬病治疗领域，公司抗狂犬病血清产品用于狂犬病的预防。 同时，公司拥有行业先进的抗血清抗毒素药物研发实力、经验丰富的研发团队、GMP认证的生产设施、辐射全国的医学推广团队，覆盖从抗血清抗毒素新药临床前研究和临床试验、生产与销售的全产业链，在抗血清抗毒素治疗领域具有较强的竞争力。 公司经过多年的研究积累，在抗血清相关急救药品的研发上具备较强的领先优势。公司的产品抗蛇毒血清、抗狂犬病血清已纳入《国家基本药物目录》；抗蛇毒血清、马破免疫球蛋白、抗狂犬病血清已全部纳入了国家人社部颁发的《国家基本医疗保险、工伤保险和生育保险药品目录》；抗蛇毒血清和马破免疫球蛋白已纳入国家卫计委《急（抢）救药品直接挂网采购示范药品目录》。 公司坚持以履行社会责任、保障人民群众的生命安全为出发点，在现有研发领域及其相关产品具有专科、急救、涉及公共安全等特殊性的基础上，以抗血清领域为核心的研发方向，通过深耕专业领域，依托抗血清技术平台，不断拓展不同类型生物毒素抗血清研发，致力于成为生物毒素及生物安全预防与治疗领域药物开发的领军企业。 | ||||||||||||||||||||||||
| Main Business | 研究、开发、生产及销售针对生物毒素及生物安全领域的预防和治疗药物。 | ||||||||||||||||||||||||
| Legal Representative | 范志和 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 成琼 | ||||||||||||||||||||||||
| Solicitors | 上海市锦天城律师事务所 | ||||||||||||||||||||||||
| Auditors | 天职国际会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 021-64959122 | ||||||||||||||||||||||||
| Fax No | 021-64959122 | ||||||||||||||||||||||||
| Website | www.serum-china.com.cn | ||||||||||||||||||||||||
| dmb@serum-china.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 11/03/2022 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.360 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.200 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 10.034 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 0.914B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |